热门资讯> 正文
Avidity报告BLA前会议对Duchenne肌肉萎缩症资产del-zota的积极评价
2025-10-13 23:05
- Avidity Biosciences (NASDAQ:RNA) said that it will submit a BLA for its Duchenne muscular dystrophy candidate delpacibart zotadirsen (del-zota) in Q1 2026 following a pre-BLA meeting with the US FDA.
- The submission was originally planned for by the end of 2025, but has been changed "to ensure the FDA receives additional data to support the chemistry, manufacturing, and controls package at time of submission," the company stated.
- Del-zota has Breakthrough Therapy designation and is under investigation for individuals with Duchenne muscular dystrophy who have gene mutations amenable to exon 44 skipping (DMD44).
More on Avidity Biosciences
- Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota
- Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript)
- Redefining the Treatment of Duchenne Muscular Dystrophy Presentation
- Avidity Biosciences prices $600M stock offering
- Avidity Biosciences reports data from DMD treatment trials
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
